Arvinas Inc. (ARVN)
NASDAQ: ARVN
· Real-Time Price · USD
6.95
-0.68 (-8.91%)
At close: May 06, 2025, 3:59 PM
6.95
0.00%
Pre-market: May 07, 2025, 05:19 AM EDT
-8.91% (1D)
| Bid | 6.55 |
| Market Cap | 507.29M |
| Revenue (ttm) | 426.9M |
| Net Income (ttm) | -46.6M |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | -10.53 |
| Forward PE | -1.87 |
| Analyst | Buy |
| Ask | 7.95 |
| Volume | 2,188,515 |
| Avg. Volume (20D) | 2,845,880 |
| Open | 7.59 |
| Previous Close | 7.63 |
| Day's Range | 6.92 - 7.68 |
| 52-Week Range | 5.94 - 37.38 |
| Beta | 2.23 |
About ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2018
Employees 430
Stock Exchange NASDAQ
Ticker Symbol ARVN
Website https://www.arvinas.com
Analyst Forecast
According to 17 analyst ratings, the average rating for ARVN stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 87.05% from the latest price.
Stock ForecastsEarnings Surprise
Arvinas has released their quartely earnings
on May 1, 2025:
6 days ago
-24.84%
Arvinas shares are trading lower. The company repo...
Unlock content with
Pro Subscription
1 month ago
-52.73%
Arvinas shares are trading lower after the company announced topline results from the phase 3 VERITAC-2 Trial of Vepdegestrant Monotherapy Versus Fulvestrant in adults with advanced or retastatic breast cancer.
